Innoviva's IST unit posts 45% U.S. sales growth as NUZOLVENCE launches
Innoviva reported third-quarter 2026 results on November 4, with its specialty therapeutics business on track to meet 2026 guidance and a newly launched gonorrhea antibiotic.
SEC filing